TVTX 8-K 2026-09-21
Travere Therapeutics, Inc. (TVTX) 8-K dated 2026-09-21 — accession 0001438533-26-000068.
Travere Therapeutics, Inc. (TVTX) is a biotechnology company listed on US.
Travere Therapeutics, Inc. filed a 8-K on 2026-09-21. Accession 0001438533-26-000068.
This 8-K covers: Director/officer change (Item 5.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported TVTX revenue for 2025-12-31 was $490.7M. Net income was -$25.5M. Revenue was up 110.5% from 2024-12-31 to 2025-12-31. TVTX currently screens at market cap $1.33B.
Not investment advice. The TVTX SEC hub lists recent forms. The stock page is the research view.